HACKENSACK, N.J. - Merck & Co. subsidiary Organon has agreed to a $100 million nationwide settlement of all claims alleging blood clot injuries from the NuvaRing contraceptive device, according to a master settlement agreement filed Feb. 7 in a New Jersey and a federal court (In Re: NuvaRing Litigation, No. 284, N.J. Super., Bergen Co.; In Re: NuvaRing Products Liability Litigation, MDL Docket No. 1964, No. 4:08-md-1964, E.D. Mo.).